您当前所在的位置:首页 > 产品中心 > 产品信息
Edrophonium_分子结构_CAS_116-38-1)
点击图片或这里关闭

Edrophonium

产品号 DB01010 公司名称 DrugBank
CAS号 116-38-1 公司网站 http://www.ualberta.ca/
分子式 C10H16NO+ 电 话 (780) 492-3111
分子量 166.24014 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 883

产品价格信息

请登录

产品别名

标题
Edrophonium
IUPAC标准名
N-ethyl-3-hydroxy-N,N-dimethylanilinium
IUPAC传统名
edrophonium
商标名
Enlon Plus
Tensilon chloride
Reversol
Antirex
Enlon
Tensilon
别名
Edrophone Chloride
Edrophonium Ion
EDR
Edrophonium Chloride
Edrophonum

产品登记号

CAS号 116-38-1
PubChem SID 46507530
PubChem CID 3202

产品性质

疏水性(logP) -2.95
溶解度 Appreciable as liquid hydrochloride salt

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. [PubChem]
Indication For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
Pharmacology Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Nicotinic acetylcholine (nAChR)receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the nicotinic acetylcholine receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetylcholine allow the remaining receptors to function more efficiently.
Toxicity With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).
Affected Organisms
Humans and other mammals
Absorption Rapidly absorbed.
Half Life Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.
Elimination Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine.
Hepatic metabolism and biliary excretion have also been demonstrated in animals
Distribution * 1.6±0.4 L/kg [Adults]
* 2.2±1.5 L/kg [Children (0.08-10 yrs)]
* 1.8±1.2 L/kg [Elderly (65-75 yrs)]
Clearance * 6.8 +/- 2. mL/kg/min [Adults]
* 6.4 +/- 3.9 mL/kg/min [Children (0.08-10 yrs)]
* 2.9 +/- 1.9 mL/kg/min [Elderly (65-75 yrs)]
External Links
Wikipedia
RxList
Drugs.com

参考文献